Market Access & Health Economics in Portugal: Eurotrials supports market access strategy

market access portugal

In 2016, INFARMED (the Portuguese National Authority of Medicines and Health Products) approved 51 innovative drugs and 6 generics, which is a 38% increase of marketing authorizations conceded when compared to 2015.

One of the main highlights is the oncology area, with 13 new drugs, and new treatments for rheumatic diseases, HIV, hepatitis C and Parkinson disease. Regarding generics, 6 new active compounds were approved, with 2 biosimilars.

Eurotrials is proud to have contributed to the access of some of these drugs and generics to the Portuguese market, specialy with the project of two high impact drugs in the hematology-oncology, which treats and prevents blood diseases and cancers such as iron-deficiency anemia, hemophilia, sickle-cell disease, leukemia and lymphoma. Our main contributions are related with our Regulatory Affairs and Health Economics areas, with regulatory and market access strategy support, the conduction of experts’ panels, pharmacotheurapeutic and pharmacoeconomic reports.

You can read more information related with our services at our page, Health Economics, or you can contact us through the submission of this form.

If you wish to know all the approved drugs and generics, you can access INFARMED press release here.

 

Source: INFARMED

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedInShare on Tumblr